Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lambda-bis(2,2'-bipyridine)-(5-methyl-2-2'-bipyridine)-C9-adamantane ruthenium (II) is a ruthenium(II) coordination complex featuring bipyridine and adamantane ligands. This compound belongs to a class of ruthenium complexes extensively investigated for their potential biological activities, particularly as anticancer agents. Its mechanism of action is thought to involve interactions with DNA, leading to DNA damage, and the induction of oxidative stress through the generation of reactive oxygen species (ROS). Some related ruthenium complexes demonstrate enhanced cytotoxicity upon photoactivation, suggesting a potential role in photochemotherapy. The presence of the bulky adamantane group may influence its pharmacokinetic properties and cellular interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lambda-bis(2,2'-bipyridine)-(5-methyl-2-2'-bipyridine)-C9-adamantane ruthenium (II).